Q1 Earnings Estimate for AMLX Issued By HC Wainwright

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Amylyx Pharmaceuticals in a research report issued to clients and investors on Friday, November 7th. HC Wainwright analyst A. Fein anticipates that the company will post earnings of ($0.40) per share for the quarter. HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Amylyx Pharmaceuticals’ current full-year earnings is ($2.20) per share. HC Wainwright also issued estimates for Amylyx Pharmaceuticals’ Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.39) EPS and Q4 2026 earnings at ($0.39) EPS.

Several other equities analysts have also recently issued reports on the stock. Bank of America upped their target price on shares of Amylyx Pharmaceuticals from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Friday, October 3rd. Lifesci Capital upgraded shares of Amylyx Pharmaceuticals to a “strong-buy” rating in a research report on Monday, October 27th. Robert W. Baird lifted their target price on shares of Amylyx Pharmaceuticals from $10.00 to $19.00 and gave the stock an “outperform” rating in a research report on Thursday, October 16th. Citigroup boosted their target price on shares of Amylyx Pharmaceuticals from $12.00 to $20.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Amylyx Pharmaceuticals in a research note on Wednesday, October 8th. Three research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $17.25.

Amylyx Pharmaceuticals Price Performance

Amylyx Pharmaceuticals stock opened at $12.68 on Monday. Amylyx Pharmaceuticals has a one year low of $2.60 and a one year high of $16.96. The business’s fifty day moving average is $13.30 and its 200 day moving average is $8.99. The stock has a market capitalization of $1.39 billion, a PE ratio of -7.04 and a beta of -0.34.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its earnings results on Thursday, November 6th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.06.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Hsbc Holdings PLC raised its stake in Amylyx Pharmaceuticals by 24.7% during the 1st quarter. Hsbc Holdings PLC now owns 14,419 shares of the company’s stock worth $51,000 after acquiring an additional 2,853 shares during the period. California State Teachers Retirement System bought a new position in shares of Amylyx Pharmaceuticals in the second quarter worth approximately $28,000. BNP Paribas Financial Markets increased its stake in shares of Amylyx Pharmaceuticals by 433.2% in the second quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company’s stock worth $47,000 after purchasing an additional 5,904 shares in the last quarter. R Squared Ltd raised its position in shares of Amylyx Pharmaceuticals by 99.9% during the 1st quarter. R Squared Ltd now owns 12,736 shares of the company’s stock valued at $45,000 after purchasing an additional 6,366 shares during the period. Finally, Ameritas Investment Partners Inc. bought a new stake in shares of Amylyx Pharmaceuticals during the 2nd quarter valued at $45,000. 95.84% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CEO Joshua B. Cohen sold 29,933 shares of Amylyx Pharmaceuticals stock in a transaction on Tuesday, September 30th. The shares were sold at an average price of $14.35, for a total transaction of $429,538.55. Following the transaction, the chief executive officer owned 3,325,347 shares in the company, valued at $47,718,729.45. This trade represents a 0.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Gina Mazzariello sold 8,828 shares of the firm’s stock in a transaction on Tuesday, September 30th. The stock was sold at an average price of $14.58, for a total value of $128,712.24. Following the completion of the transaction, the insider directly owned 148,141 shares in the company, valued at approximately $2,159,895.78. This represents a 5.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 91,333 shares of company stock valued at $1,319,495. 12.30% of the stock is currently owned by corporate insiders.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.